76IN - Targeted treatment of NETs

Date 29 September 2012
Event ESMO Congress 2012
Session Integrating targeted treatments with tumor biology and molecular imaging in the current and future management of neuroendocrine gastrointestinal tumors
Topics Anticancer agents
Neuroendocrine Cancers
Biological therapy
Presenter James Yao
Authors J.C. Yao
  • Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US


Low to intermediate grade neuroendocrine tumor (NET) constitutes a group of malignancies that share the capacity for secreting hormones and causing distinctive clinical syndromes. Until recently, there were few evidence-based treatment options. Recent advances in targeted therapy and completion of pivotal phase III studies have brought the approval of both everolimus and sunitinib for pancreatic NET. These large randomized studies demonstrated improvement of progression-free survival validating the PI3K/Akt/mTOR pathway and angiogenesis as important targets for further advances. These studies also showed some of the challenges of NET including patient accrual and disease heterogeneity. Ongoing phase III studies comparing bevacizumab versus interferon and everolimus versus placebo among patients with other NET subtypes may bring much needed advances in areas of unmet need. Development of rational combinations is also ongoing. These ongoing studies as well as our improved understanding of the underlying molecular biology will bring needed advances.


J.C. Yao: Consultant relationship with Ipsen, Lexicon, Novartis, Pfizer.